Current treatment status-Did not start treatment yet - Page 26 of 37 Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Fifteen-year outcomes following conservative management of prostate cancer

Fifteen-year outcomes following conservative management of prostate cancer

Posted by on May 29, 2015 in Prostate cancer | 0 comments

In a nutshell This study investigated the long-term outcomes of conservative management of localized prostate cancer in men aged 65 and over. Some background Increased levels of prostate specific antigen (PSA; a protein elevated in prostate cancer) screening is allowing the detection of prostate cancer when it has not yet spread to other parts of...

Read More

Looking for prostate cancer patients to evaluate the effect of hypofractionated radiation treatment

Posted by on May 6, 2015 in Prostate cancer | 0 comments

In a nutshell This phase I-II trial in the US aims to determine whether hypofractionated proton beam radiation therapy can achieve the same treatment benefits as current conventional radiation therapy in prostate cancer patients. The main outcome to be investigated is whether hypofractionated radiation can successfully maintain and control prostate...

Read More

Can levels of antimullerian hormone predict when patients with breast cancer regain ovarian function?

Can levels of antimullerian hormone predict when patients with breast cancer regain ovarian function?

Posted by on Apr 28, 2015 in Breast cancer | 0 comments

In a nutshell This paper studied whether levels of antimullerian hormone, follicle stimulating hormone and inhibin B could predict when the ovaries regain function after chemotherapy.  Some background Chemotherapy is used to treat breast cancer. However, it can cause damage to the ovaries and affect fertility. Thus, it would be useful for...

Read More

Is capecitabine better with lapatinib or trastuzumab for HER2 positive metastatic breast cancer?

Is capecitabine better with lapatinib or trastuzumab for HER2 positive metastatic breast cancer?

Posted by on Apr 28, 2015 in Breast cancer | 0 comments

In a nutshell This paper studied the effect of lapatinib (Tyverb) plus capecitabine (Xeloda) versus trastuzumab (Herceptin) plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other parts of the body. Some background Trastuzumab is used  to treat HER2 positive breast...

Read More

Selumetinib in eye cancer treatment

Selumetinib in eye cancer treatment

Posted by on Apr 21, 2015 in Melanoma | 0 comments

In a nutshell The authors aimed to determine the effect of selumetinib in treating eye cancer compared to chemotherapy. Some background Uveal melanoma (eye cancer) is a rare form of cancer that occurs in the eye and has a 50% rate of metastasis (cancer spreads from the original site around the body). Selumetinib (AZD6244) is a drug that...

Read More

Interleukin-2 can improve survival in skin cancer patients

Posted by on Apr 21, 2015 in Melanoma | 0 comments

In a nutshell The authors aimed to determine the effect of interleukin-2 in treating in-transit skin cancer.  Some background In-transit skin cancer is cancer that has progressed into the lymph nodes (sites that hold the immune cells) from the primary site of cancer. Interleukin-2 (IL-2, Proleukin,  Aldesleukin) is a man-made protein...

Read More

Blood protein predicts future response to rheumatoid arthritis therapy

Blood protein predicts future response to rheumatoid arthritis therapy

Posted by on Apr 11, 2015 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether MRP8/14 protein levels can predict rheumatoid arthritis patient response to biologic drug treatment. Some background Rheumatoid arthritis is an inflammatory disease affecting the joints, the connections between bones. The goal of drug therapy is remission: a time when the disease is not active and...

Read More

Is a unique paclitaxel plus trastuzumab treatment effective in HER2 positive breast cancer?

Is a unique paclitaxel plus trastuzumab treatment effective in HER2 positive breast cancer?

Posted by on Apr 7, 2015 in Breast cancer | 0 comments

In a nutshell This paper studied the safety and effectiveness of treatment with a unique form of paclitaxel (Taxol) and trastuzumab (Herceptin) in human epidermal growth factor receptor 2 positive breast cancer.  Some background Chemotherapy is widely used before surgery in breast cancer to reduce the size of the tumour before surgical...

Read More